about
Medical management of uveitis - current trendsAngiotensin-converting enzyme 2 (ACE2) activator diminazene aceturate ameliorates endotoxin-induced uveitis in miceGenome-wide retinal transcriptome analysis of endotoxin-induced uveitis in mice with next-generation sequencingRapamycin ameliorates experimental autoimmune uveoretinitis by inhibiting Th1/Th2/Th17 cells and upregulating CD4+CD25+ Foxp3 regulatory T cells.Understanding autoimmunity in the eye: from animal models to novel therapies.Role of the retinal vascular endothelial cell in ocular diseaseAAV8-Mediated Angiotensin-Converting Enzyme 2 Gene Delivery Prevents Experimental Autoimmune Uveitis by Regulating MAPK, NF-κB and STAT3 PathwaysActivation of liver X receptor alleviates ocular inflammation in experimental autoimmune uveitis.Biologic agents in experimental autoimmune uveitis.New pharmacotherapy options for noninfectious posterior uveitis.Vorinostat Modulates the Imbalance of T Cell Subsets, Suppresses Macrophage Activity, and Ameliorates Experimental Autoimmune Uveoretinitis.Modulating of ocular inflammation with macrophage migration inhibitory factor is associated with notch signalling in experimental autoimmune uveitis.Experimental uveitis can be maintained in rabbits for a period of six weeks after a safe sensitization method.The effect of mesenchymal stem cells on dynamic changes of T cell subsets in experimental autoimmune uveoretinitis.Modern Therapeutic Approaches for Noninfectious Ocular Diseases Involving Inflammation.[Treatment of posterior noninfectious uveitis : Current situation and future developments].
P2860
Q27003399-BE0BF1A7-86A4-4B4A-ABB7-665547217567Q33773490-2FEF5ADC-B0F8-4282-BCBF-B97608B710CAQ33884579-5A24EF3D-8599-49B1-9273-032EA60192D9Q35964539-817F4C20-1C42-451D-90EE-B775A94618ACQ36069594-E5905A81-F5FF-4537-AF3F-758334907EB2Q36919959-F9BE72AF-12AA-4E80-8A83-ABD1118B8C40Q37202385-0B5E997E-EEF7-4817-96D4-E085EF34790BQ37731895-960A6E1F-A6E1-4E96-8E84-AA58E9A22DF4Q38089645-61677BC6-7696-49FC-9607-55871869695CQ38253095-276DC1B4-C6CE-4A16-AB50-90DB33A8A6DDQ40075215-4FAC8CE2-5D7F-4E73-8EC1-471468C38831Q40508949-A027B5EF-BBED-4DEE-8E8C-8EE83602D90AQ44436609-B00A74C3-84EE-4134-99CD-1A9258AE84C4Q46330875-C20F9D9D-AA8E-45BF-AAC9-97412975F236Q47442388-10488EB1-74A6-40CF-9926-9B2BF5352822Q52852545-1F0AE473-5954-4A14-8E91-9157CC83B286
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Biological agents for the treatment of uveitis.
@en
Biological agents for the treatment of uveitis.
@nl
type
label
Biological agents for the treatment of uveitis.
@en
Biological agents for the treatment of uveitis.
@nl
prefLabel
Biological agents for the treatment of uveitis.
@en
Biological agents for the treatment of uveitis.
@nl
P2093
P2860
P1476
Biological agents for the treatment of uveitis
@en
P2093
Evan H Black
John J Huang
Katrina A Mears
P2860
P304
P356
10.1517/14712598.2012.658366
P407
P577
2012-03-01T00:00:00Z